View in EDS HTML Full Text PDF Full Text

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.

Saved in:
Bibliographic Details
Title: Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
Authors: Denlinger CS; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. Crystal.Denlinger@fccc.edu., Keedy VL; Department of Medicine (Hematology and Oncology), Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Moyo V; Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA., MacBeath G; Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA., Shapiro GI; Dana-Farber Cancer Institute, Boston, MA, USA.
Source: Investigational new drugs [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1604-1612. Date of Electronic Publication: 2021 Jul 11.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34250553
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Denlinger+CS%22">Denlinger CS</searchLink>; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. Crystal.Denlinger@fccc.edu.<br /><searchLink fieldCode="AU" term="%22Keedy+VL%22">Keedy VL</searchLink>; Department of Medicine (Hematology and Oncology), Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Moyo+V%22">Moyo V</searchLink>; Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22MacBeath+G%22">MacBeath G</searchLink>; Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Shapiro+GI%22">Shapiro GI</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1604-1612. <i>Date of Electronic Publication: </i>2021 Jul 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34250553
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-021-01145-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1604
    Titles:
      – TitleFull: Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Denlinger CS
      – PersonEntity:
          Name:
            NameFull: Keedy VL
      – PersonEntity:
          Name:
            NameFull: Moyo V
      – PersonEntity:
          Name:
            NameFull: MacBeath G
      – PersonEntity:
          Name:
            NameFull: Shapiro GI
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Numbering:
            – Type: volume
              Value: 39
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1